secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001437749-25-031210
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 3.03, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex granted Nasdaq exception through Oct 31, 2025; 1-for-50 reverse stock split effective Oct 21
--------------------------------------------------------------------------------

- Nasdaq Panel exception to demonstrate compliance with $1.00 bid price and $2.5M stockholders' equity until Oct 31, 2025; Panel may extend to Feb 9, 2026.
- 1-for-50 reverse stock split filed Oct 16, effective Oct 21, 2025; CUSIP changes to 372446-302; symbol remains GNPX.
- Acclaim-1 (REQORSA + Tagrisso) Phase 2a enrollment ongoing; interim analysis of first 19 patients expected H2 2026.
- Acclaim-3 (REQORSA + Tecentriq) Phase 2 expansion enrolling; futility analysis after 25th patient expected H2 2026.
- Diabetes gene therapy GPX-002 in preclinical studies; plans to request FDA meeting for IND-enabling studies by end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/0001437749-25-031210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/gnpx20251001_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-031210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer